AI-generated summary
This review describes current understanding of non-advanced age-related macular degeneration, including imaging biomarkers, functional tests, and risk factors. The authors report that no pharmacologic therapies are approved for this stage, and that photobiomodulation shows preliminary promise but needs validation in robust, adequately powered randomized trials.
- Who or what was studied
- People with early and intermediate (non-advanced) age-related macular degeneration
- Limits stated in the abstract
- The abstract states that photobiomodulation evidence is preliminary and requires validation in robust, adequately powered randomized clinical trials.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Age-related macular degeneration, Photobiomodulation, Heterogeneity, Biomarker, Laser. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.